Compare IMXI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | CCCC |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 404.7M |
| IPO Year | 2016 | 2020 |
| Metric | IMXI | CCCC |
|---|---|---|
| Price | $14.99 | $3.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $15.00 | $12.20 |
| AVG Volume (30 Days) | 446.4K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $319,601,000.00 | $35,947,000.00 |
| Revenue This Year | $0.83 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $744.00 | ★ N/A |
| Revenue Growth | ★ 16.68 | 1.02 |
| 52 Week Low | $8.58 | $1.36 |
| 52 Week High | $15.95 | $4.60 |
| Indicator | IMXI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 56.80 |
| Support Level | $14.86 | $2.17 |
| Resistance Level | $15.19 | $4.60 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 52.86 | 42.33 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.